Proteomics for hematopoietic stem cell transplantation

Expert Rev Proteomics. 2020 Mar;17(3):201-206. doi: 10.1080/14789450.2020.1748501. Epub 2020 Apr 4.


Introduction: After the genomic era, the analysis of the proteome has gained increasing importance. Peptides and/or proteins present in tissue or body fluids can depict health and are prone to change during disease, not only in configuration but also in abundance. Early on, high throughput proteome analysis was implemented in the diagnostic of therapy-linked or induced complications arising after allogeneic hematopoietic stem cell transplantation (HSCT). Several proteomic approaches are currently used in the prediction or diagnosis of acute and/or chronic graft-versus-host disease (GvHD).Areas covered: This review will report on two high throughput proteomics technologies used in the clinical setting to date, namely enzyme-linked-immunosorbent assays (ELISA) for key proteins involved in the pathogenesis of acute GvHD and on capillary electrophoresis coupled on-line to mass spectrometry (CE-MS). Here, we summarize the current data and discuss the strength as well as the limitations of each method and compare the usefulness and practicability in the post-HSCT setting for prediction and diagnosis of acute GvHD.Expert commentary: Both technologies are applied in the clinic and have been tested on several hundred patients after HSCT. The data from both technologies may complement each other in diagnosis of GvHD.

Keywords: Clinical proteomics; biomarkers; graft-versus-host disease; stem cell transplantation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Enzyme-Linked Immunosorbent Assay
  • Graft vs Host Disease / diagnosis*
  • Graft vs Host Disease / genetics
  • Graft vs Host Disease / pathology
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Mass Spectrometry
  • Proteome / genetics*
  • Proteomics*


  • Proteome